Overview

Pharmacokinetic Interaction Study to Assess the Effect of Repeat Doses of Rifampin on Mirabegron (YM178) in Healthy Volunteers

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The objective of the study is to assess the PK, safety and tolerability of a single dose of mirabegron alone and in combination with repeat doses of rifampin, a potent CYP3A4 inducer.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Mirabegron
Rifampin